Basic Information
| LncRNA/CircRNA Name | lnc-DILC |
| Synonyms | TFDP1, DILC, DP1, DRTF1, Dp-1 |
| Region | GRCh38_13:113584721-113641470 |
| Ensemble | ENSG00000198176 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, in vitro knockdown, Luciferase reporter assay etc. |
| Sample | cell line (HCT116,SW480), CRC tissues |
| Expression Pattern | down-regulated |
| Function Description | lnc-DILC overexpression inhibited the growth and metastasis of CRC cells. Consistently, lnc-DILC knockdown facilitated the proliferation and metastasis of CRC cells. Mechanically, lnc-DILC suppressed CRC cell progression via IL-6/STAT3 signaling inactivation. More importantly, the specific STAT3 inhibitor S3I-201 and IL-6R inhibitor tocilizumab abolished the discrepancy of growth and metastasis capacity between lnc-DILC-interference CRC cells and control cells, which further confirmed that IL-6/STAT3 signaling was required in lnc-DILC-disrupted CRC cell growth and metastasis. Taken together, our results suggest that lnc-DILC is a novel CRC suppressor and may prove to be an inhibitor of CRC progression by inactivating IL-6/STAT3 signaling. |
| Pubmed ID | 29621586 |
| Year | 2018 |
| Title | Long non-coding RNA DILC suppresses cell proliferation and metastasis in colorectal cancer. |
External Links
| Links for lnc-DILC | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |